Skip to main content
Premium Trial:

Request an Annual Quote

Symyx Board Rejects 'Final' Certara Offer

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Symyx Technologies today said that its board of directors has rejected Certara's "best and final" offer to acquire Symyx for $5.75 per share in cash, or around $200 million.

It is the third time in the past two weeks that Symyx has declined Certara's bid, saying it does not constitute a superior offer to Accelrys' offer to buy the firm for $5 per share. Symyx has repeatedly said that the deal with Accelrys offers a greater upside and has urged its shareholders to back the merger with Accelrys.

Symyx said that it expects to close the deal with Accelrys, under which shareholders of each firm own around 50 percent of the combined company, at the beginning of July.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.